CovInnovations
CovInnovations is a COVID-19 therapeutic research company dedicated to developing groundbreaking technologies to assess, diagnose, and treat COVID-19. Their mission is to discover efficacious therapies, tests, and diagnostics to alleviate pandemic infectious diseases, with a vision to rid the world of infectious diseases. The company focuses primarily on a revolutionary treatment, CovArrest™, which aims to halt COVID-19 in hospitalized patients, and also develops rapid testing solutions like CovaTest™ and CovAssess™. CovInnovations is committed to creating a new standard of care for COVID-19, with products designed to significantly reduce deaths, relax restrictions, and restore normalcy.
Industries
Nr. of Employees
small (1-50)
Products
Late-stage combination therapeutic for hospitalized COVID-19 patients
A therapeutic regimen composed of two repurposed, FDA‑approved drugs designed to suppress cytokine-driven inflammation and reduce mortality and hospital length of stay in oxygen-dependent or intubated patients; supported by retrospective cohort results reporting reductions in mortality and length of stay.
Rapid RNA-based saliva diagnostic (pre-prototype)
An RNA-based rapid diagnostic intended to detect SARS‑CoV‑2 and identify strain variants from a saliva sample with results targeted in minutes; currently in pre-prototype development for home or point-of-care use.
Dual-marker COVID-19 susceptibility test (development)
A laboratory or point-of-care test under development that measures two biomarkers to estimate an individual’s likelihood of contracting SARS‑CoV‑2 and risk for severe disease or mortality.
Late-stage combination therapeutic for hospitalized COVID-19 patients
A therapeutic regimen composed of two repurposed, FDA‑approved drugs designed to suppress cytokine-driven inflammation and reduce mortality and hospital length of stay in oxygen-dependent or intubated patients; supported by retrospective cohort results reporting reductions in mortality and length of stay.
Rapid RNA-based saliva diagnostic (pre-prototype)
An RNA-based rapid diagnostic intended to detect SARS‑CoV‑2 and identify strain variants from a saliva sample with results targeted in minutes; currently in pre-prototype development for home or point-of-care use.
Dual-marker COVID-19 susceptibility test (development)
A laboratory or point-of-care test under development that measures two biomarkers to estimate an individual’s likelihood of contracting SARS‑CoV‑2 and risk for severe disease or mortality.
Services
Preparation of written clinical trial protocols suitable for international deployment and Phase III testing of a late-stage therapeutic.
Internal program management and coordination with external regulatory specialists to prepare Pre-IND, IND, and EUA submissions.
Collaborative research agreements with academic institutions to conduct preclinical and clinical research for therapeutic and diagnostic development.
Booking of initial consultations with clinical team members to assess care options or trial eligibility.
Preparation of written clinical trial protocols suitable for international deployment and Phase III testing of a late-stage therapeutic.
Internal program management and coordination with external regulatory specialists to prepare Pre-IND, IND, and EUA submissions.
Collaborative research agreements with academic institutions to conduct preclinical and clinical research for therapeutic and diagnostic development.
Booking of initial consultations with clinical team members to assess care options or trial eligibility.
Expertise Areas
- Clinical trial management
- Regulatory strategy and FDA submissions (Pre-IND / IND / EUA)
- COVID-19 therapeutic development using repurposed drugs
- Point-of-care RNA diagnostic development
Key Technologies
- RNA-based rapid diagnostics (saliva)
- Dual-marker susceptibility assays
- Drug repurposing and combination therapy
- Clinical trial protocol design
News & Updates
Covinnovations™ received positive comments on its funding application to NIH, emphasizing the science behind COVID treatment COVI-001 and the expertise of its team.
Covinnovations™ was awarded a Technical Watch meeting with BARDA to discuss its COVID-19 treatment technology and explore potential partnership.
Covinnovations™ was invited to participate in the 2022 Biotech Showcase to highlight its COVID-19 treatment CovArrest™.
Key management attended the IBE conference and submitted a Pre-IND request for CovArrest™, seeking FDA authorization for Phase III trials.
Throughout summer, CovInnovations™ advanced clinical trials, manufacturing, and international relations for CovArrest™.
The company secured $480,000 to accelerate FDA approval for CovArrest™ and develop other COVID-19 related tests.
Covinnovations™ received positive comments on its funding application to NIH, emphasizing the science behind COVID treatment COVI-001 and the expertise of its team.
Covinnovations™ was awarded a Technical Watch meeting with BARDA to discuss its COVID-19 treatment technology and explore potential partnership.
Covinnovations™ was invited to participate in the 2022 Biotech Showcase to highlight its COVID-19 treatment CovArrest™.
Key management attended the IBE conference and submitted a Pre-IND request for CovArrest™, seeking FDA authorization for Phase III trials.
Throughout summer, CovInnovations™ advanced clinical trials, manufacturing, and international relations for CovArrest™.
The company secured $480,000 to accelerate FDA approval for CovArrest™ and develop other COVID-19 related tests.